Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

Main|Search|PHGKB



Last Posted: Jul 16, 2017

---

• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer  
  E Hahnen et al, JAMA Oncology, July 2017
• Take Action to Lower Your Breast and Ovarian Cancer Risk  
• Current condition of genetic medicine for hereditary breast cancer.  
  Terui-Kohbata Hiroko et al. Molecular and clinical oncology 2017 Jul 7(1) 98-102
• Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.  
  Lee Jihyoun et al. Journal of breast cancer 2017 Jun 20(2) 203-207
• The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.  
  MacDonald Karen V et al. European journal of cancer (Oxford, England : 1990) 2016 Jul 6185-93
• Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?  
  Partridge Ann H et al. Breast cancer research and treatment 2017 Jun
• Test gives accurate prognosis for breast cancer patients with 'ultralow' risk  
  A Sandou, Medical News Today, June 30, 2017
• Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.  
  Esserman Laura J et al. JAMA oncology 2017 Jun
• Test gives accurate prognosis for breast cancer patients with 'ultralow' risk  
  A Sandou, Medical News Today, June 30, 2017
• Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades  
  LJ Esserman et al., JAMA Oncology, June 28, 2017
• Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.  
  Thakur Sunitha B et al. Journal of magnetic resonance imaging : JMRI 2017 Jun
• BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.  
  Pilato Brunella et al. Genes, chromosomes & cancer 2016 Oct 55(10) 803-13
• Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.  
  Grindedal Eli Marie et al. BMC cancer 2017 Jun 17(1) 438
• Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.  
  Buzolin Ana Lígia et al. Human genomics 2017 Jun 11(1) 14
• The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.  
  Afghahi Anosheh et al. Current treatment options in oncology 2017 May 18(5) 27
• The Role of Genetic Testing in Patients With Breast Cancer: A Review.  
  Valencia Olivia M et al. JAMA surgery 2017 Jun 152(6) 589-594

more